• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Seaport Calibre Materials Acquisition Corp.

    1/31/23 11:56:40 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous
    Get the next $SCMA alert in real time by email
    DEFA14A 1 tm235015d1_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    Schedule 14A

     

     

     

    Information Required in Proxy Statement
    Schedule 14A Information

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

     

    Filed by the Registrant   x
    Filed by a Party other than the Registrant   ¨

     

    Check the appropriate box:

     

    ¨   Preliminary Proxy Statement
    ¨   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨   Definitive Proxy Statement
    x   Definitive Additional Materials
    ¨   Soliciting Material Pursuant to § 240.14a-12

     

    Seaport Calibre Materials Acquisition Corp.
    (Name of Registrant as Specified in its Charter)

    _________________________________________________________________

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x   No fee required.
    ¨   Fee paid previously with preliminary materials.
    ¨   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    Seaport Calibre Materials Acquisition Corp.

    260 Madison Avenue, 20th Floor

    New York, NY 10017

     

    SUPPLEMENT TO

    PROXY STATEMENT DATED JANUARY 13, 2023

    FOR SPECIAL MEETING

    OF

    SEAPORT CALIBRE MATERIALS ACQUISITION CORP

     

    Dear Stockholders of Seaport Calibre Materials Acquisition Corp:

     

    Seaport Calibre Materials Acquisition Corp., a Delaware corporation (the “company”, “we”, “us” or “our”) previously filed its definitive proxy statement dated January 13, 2023 (the “Proxy Statement”) in connection with its special meeting to be held virtually on January 31, 2023, at 1:00 P.M., Eastern time (the “special meeting”), which will be conducted via live webcast register to attend at https://www.cstproxy.com/seaportcalibreacquisition/2023 and via teleconference using the following dial-in information:

     

    Telephone access (listen-only):

    Within the U.S. and Canada:

    1 800-450-7155 (toll-free)

    Outside of the U.S. and Canada:

    +1 857-999-9155 (standard rates apply)

    Conference ID: 7493202#

     

    The purpose of this document is to supplement the Proxy Statement with certain additional information as follows:

     

    Additional Trust Disclosure. Based upon the current amount in the Trust Account, the Company estimates that the per-share price at which public shares will be redeemed from cash held in the Trust Account will be $10.27262364.

     

    Participants in the Solicitation. The company and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the company’s shareholders in respect of the special meeting and related matters. Information regarding the company’s directors and executive officers is available in company’s Proxy Statement dated January 13, 2023. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests are contained in the Proxy Statement.

     

    No Offer or Solicitation. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

     

    Additional Information. The company has filed with the Securities and Exchange Commission (the “SEC”) the Proxy Statement in connection with the special meeting to consider and vote upon the Extension Proposal and other matters and, beginning on or about January 13, 2023, mailed the Proxy Statement and other relevant documents to its stockholders as of the January 5, 2023 record date for the Meeting. The company’s stockholders and other interested persons are advised to read the Proxy Statement and any other relevant documents that have been or will be filed with the SEC in connection with the company’s solicitation of proxies for the special meeting because these documents contain important information about the company, the Extension Proposal and related matters. Stockholders may also obtain a free copy of the Proxy Statement, as well as other relevant documents that have been or will be filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: Seaport Calibre Materials Acquisition Corp., 360 Madison Avenue, 20th Floor, New York, NY 10017, (212) 616-7700.

     

     

     

    Forward-Looking Statements. This supplement includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in the Proxy Statement. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

     

    Except as set forth herein, all other information in the Proxy Statement remains unchanged. If you have previously-submitted a proxy or tendered your shares for redemption in accordance with the procedures set forth in the Proxy Statement and you do not wish to make any changes, you do not need to do anything further.

     

    This Proxy Supplement is dated January 31, 2023

     

     

     

     

     

     

    Get the next $SCMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCMA
    SEC Filings

    View All

    SEC Form 15-12G filed by Seaport Calibre Materials Acquisition Corp.

    15-12G - Seaport Calibre Materials Acquisition Corp. (0001863428) (Filer)

    2/13/23 4:33:20 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form 25-NSE filed by Seaport Calibre Materials Acquisition Corp.

    25-NSE - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/2/23 4:15:02 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    Seaport Calibre Materials Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Seaport Calibre Materials Acquisition Corp. (0001863428) (Filer)

    2/1/23 9:10:38 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seaport Calibre Materials Acquisition Corp. Announces It Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination

    NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Seaport Calibre Materials Acquisition Corp. (NASDAQ:SCMA) (the "Company") announced today that, because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (the "Amended Charter"), the Company intends to dissolve and liquidate in accordance with the provisions of the Amended Charter, effective as of the close of business on February 1, 2023. On January 13, 2023, the Company filed with the Securities and Exchange Commission a definitive proxy statement (the "Proxy Statement") in connection with a special meeting of stockholders to consider and vot

    2/1/23 9:00:00 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    Seaport Calibre Materials Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders

    NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Seaport Calibre Materials Acquisition Corp. (Nasdaq: SCMA) (the "Company") announced today that it has postponed the Company's Special Meeting of Stockholders to be held on January 26, 2023, until January 31, 2023, at 1:00 p.m. Eastern Time. The postponed Special Meeting will be completely virtual and stockholders will be able to attend the special meeting online, vote and submit questions by visiting https://www.cstproxy.com/seaportcalibreacquisition/2023. There will be no change in the record date as a result of this postponement, and proxies tendered prior to the postponed date will not need to be voted again. Stockholders may elect to redeem

    1/26/23 5:00:00 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Barclays Plc

    4 - Seaport Calibre Materials Acquisition Corp. (0001863428) (Issuer)

    8/26/22 1:50:25 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form 3: New insider Barclays Plc claimed ownership of 1,481,560 shares

    3 - Seaport Calibre Materials Acquisition Corp. (0001863428) (Issuer)

    8/26/22 10:39:08 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    $SCMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/14/24 1:28:06 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/9/24 11:04:13 AM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous

    SEC Form SC 13G/A filed by Seaport Calibre Materials Acquisition Corp. (Amendment)

    SC 13G/A - Seaport Calibre Materials Acquisition Corp. (0001863428) (Subject)

    2/14/23 3:30:17 PM ET
    $SCMA
    Other Pharmaceuticals
    Miscellaneous